Pioneering new targeted treatments
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.
September 7, 2022
GEN News highlighted recent University of Cincinnati and Cincinnati Children's Hospital Medical Center research on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments.
April 3, 2023
University of Cincinnati researchers recently published findings in the journal Cancer that found several enriched species, associated with enhanced tumor immune response, in the microbiomes of long-term pancreatic cancer survivors.
April 11, 2023
The University of Cincinnati's Atsuo Sasaki, PhD, is leading a multidisciplinary team that received National Institutes of Health funding to learn more about how an enzyme that was previously overlooked helps regulate lysosome and cellular function.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
November 7, 2022
MSN India highlighted recent research led by the University of Cincinnati's Trisha Wise-Draper about how immunotherapy and immunosuppression affects COVID-19 severity.
October 24, 2022
University of Cincinnati researchers presented results from the first-in-human trial of FLASH radiotherapy at the ASTRO 2022 annual meeting, with data suggesting FLASH may hold promise as a potential treatment for tough-to-kill tumors.
November 3, 2022
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, is co-corresponding author of new research in JAMA Oncology that provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.